Uso de sacubitril/valsartán en pacientes hospitalizados en vida real
- López García, Juan Carlos
- F. Fernández Avilés Zuzendaria
- Manuel Martínez-Sellés Zuzendaria
Defentsa unibertsitatea: Universidad Complutense de Madrid
Fecha de defensa: 2021(e)ko otsaila-(a)k 02
- Juan Tamargo Menéndez Presidentea
- Juan Francisco Delgado Jiménez Idazkaria
- José Luis Zamorano Gómez Kidea
- Esteban López de Sá Kidea
- Pedro Luis Sánchez Fernández Kidea
Mota: Tesia
Laburpena
Sacubitril/valsartan is safe when initiated during hospitalization in a clinical trial setting. Its safety in real-life population is not stablished. We compared the initiation of sacubitril/valsartan during hospitalization in a non-selected population, in Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in the Patients Stabilized From an Acute Heart Failure Episode (PIONEER-HF) trial, and in non-selected outpatients. Methods. Multicentre registry including 527 patients: 100 were started on sacubitril/valsartan during hospitalization (19.0%) and 427 as outpatients (81.0%). Clinical, analytical, and echocardiographic variables, previous therapies, and the starting dose of sacubitril/valsartan and its modification or suspension were collected throughout the follow-up...